drugset / Trial / NCT06007417

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

NCT06007417

Phase 3 Unknown 162 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.

Timeline

Start
2023-12-01
Primary completion
2025-05-01
Completion
2025-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GenSci004 Protein / enzyme biologic
Comparator Somatropin Protein / enzyme biologic

Indications

No indication recorded.